Search for: "GLAXOSMITHKLINE"
Results 1 - 20 of 582
Sorted by Relevance | Sort by Date
17 Oct, 2006 2:04 pm
... incomplete victory over grey markets or parallel trade in the Court of First Instance in Case T-168/01 GlaxoSmithKline Services Unlimited
v. Commission The judgment is of serious theoretical as well as practical interest because it shows clearly ... agreement in restriction of competition. It also decided that the General
Sales Conditions could not benefit from an exemption. GlaxoSmithKline brought an action before the Court of First Instance to have the
Commission's decision annulled. The Court ...
26 Jul, 2007 7:32 am
... will have 180 days of exclusivity to sell the product there, Ranbaxy said in a statement. The agreement paves the way for GlaxoSmithKline
to drop a lawsuit against Ranbaxy, that was filed in a U.S. court to prevent it from selling generic copies of Valtrex. ... of the top global pharmaceutical companies to increasingly
collaborate with generic rivals even as both compete in the same markets. GlaxoSmithKline brought the lawsuit after the U.S. Food and Drug
Administration gave its approval to Ranbaxy ...
21 May, 2007 12:06 pm
... was definitive of a problem, because the risk may be explained by other drugs or diseases. This may be so. But what did GlaxoSmithKline do?
Did they warn doctors or the millions of uses of Avandia and notify them that at least there may be an ... as a result of recent reports of the drug's risks, according Dr. Ronald L.
Krall, the medical director for GlaxoSmithKline who said in an interview that some of the 4,450 patients enrolled in the drug trial have
dropped out because of safety concerns about ...
9 Nov, 2007 9:03 am
... a MedEffect email alert about Avandia -- as well as the related Avandamet and Avandaryl -- to inform us that GlaxoSmithKline is informing
Canadian doctors and patients about new restrictions on the use of its rosiglitazone products (Avandia, ... "is still involved in internal discussions on this matter" and that when
there is a final decision it will become public. A GlaxoSmithKline spokeswoman said the company is "working diligently with the FDA to finalize
the label, but it would be inappropriate ...
1 Nov, 2006 1:55 pm
EDWARDSVILLE, Ill. (AP) _ GlaxoSmithKline PLC has agreed to pay $63.8 million to settle a lawsuit's claims that it promoted its antidepressant
drug Paxil for use by children and adolescents while withholding negative ... if they have records of their purchases. Anyone without such documentation can get $15 returned to them. As
part of the settlement, GlaxoSmithKline denies the lawsuit's claims, including that consumers paid too much for the drugs, but the world's
second-largest pharmaceutical ...
26 Jul, 2007 9:52 pm
By Donald Zuhn -- Ranbaxy Laboratories Ltd. announced today (July 26, 2007) that it had reached an agreement with GlaxoSmithKline in which
GlaxoSmithKline would dismiss its patent infringement suit against Ranbaxy. GlaxoSmithKline had
asserted its U.S. Patent No. 4,957,924, directed to Valacyclovir Hydrochloride, against Ranbaxy, which received final approval to...
15 Nov, 2007 4:01 am
... Federal Court Holds Plaintiffs filed a securities fraud class action against Glaxosmithkline based on statements made about diabetes drug
Avandia that failed to disclose the increased risk ... heart attack. Borochoff v. Glaxosmithkline PLC, ___ F.Supp.2d ___, 2007 WL 2907812, *1
(S.D.N.Y. October 5, ... light of that risk it would be improvident to appoint the German Institutional Investor Group as lead plaintiff at this point." Id. (footnote omitted). Download
PDF file of Borochoff v. Glaxosmithkline
5 Jun, 2008 12:09 pm
... Court Holds Plaintiffs filed a putative class action against pharmaceutical company GlaxoSmithKline (GSK) and certain individual officers
and directors of GSK for violations of federal ... disclose the truth about its meta-analysis in connection with its diabetes drug, Avandia. Borochoff v. GlaxoSmithKline PLC, ___ F.Supp.2d ___ (S.D.N.Y ... studies, alone, would not be deemed large enough to adequately examine a particular question.'" Borochoff,
at 2 n.1. Download PDF file of Borochoff v. GlaxoSmithKline ...
18 Sep 1:46 pm
... for Glaxo said July 8 in court papers. "Since 2005, additional studies have been inconclusive with mixed results." "GlaxoSmithKline will
show it acted properly and responsibly in conducting its clinical trial program for Paxil, in marketing the medicine, in monitoring ... and then turned the gun on himself after taking
Paxil. The case is Kilker v. SmithKline Beecham Corp. dba GlaxoSmithKline, 2007-001813, Court of Common Pleas, Philadelphia County,
Pennsylvania. If you or a family member has been ...
17 Nov, 2005 1:54 pm
... 16 November 2005, the Federal Court of Australia released an interesting decision in the case of AstraZeneca Pty Ltd v GlaxoSmithKline
Australia Pty Ltd [2005] FCA 1645. The case involved a challenge by AstraZeneca, under the Trade Practices ... some respects to, for example, New Zealand's Fair Trading Act), against
certain advertisements by GlaxoSmithKline for its asthma product Seretide, in particular this phrase used in the advertisements: "Seretide
Total Control". AstraZeneca sought orders for ...
27 Mar, 2007 5:32 pm
In advance of a hearing in New Zealand in relation to claims that the manufacturers of Ribena may have misled consumers about the Vitamin C content of Ribena blackcurrant fruit drink
products, GlaxoSmithKline Australia Pty Limited self-reported the discrepancies to the Australian Competition and Consumer Commission and
provided court enforceable undertakings. More
29 Apr, 2008 9:21 pm
By Donald Zuhn -- Last Tuesday, GlaxoSmithKline and Sirtris Pharmaceuticals announced that the companies had entered into a definitive
agreement under which GlaxoSmithKline would acquire Sirtris Pharmaceuticals for approximately $720 million. The acquisition is motivated by
GSK's desire to enhance its metabolic, neurology, immunology, and inflammation research efforts by utilizing...
14 May, 2008 5:20 am
/**/ Antitrust Class Action by Assignees of Direct Purchasers of Antidepressant Wellbutrin SR Satisfied Rule 23 Class Action Requirements Pennsylvania Federal Court Holds Plaintiffs
filed a class action complaint against SmithKline Beecham Corporation dba GlaxoSmithKline (GSK) alleging antitrust violations arising out of
its manufacture and sale of the antidepressant drug Wellbutrin SR. The class action purports to be filed on behalf of "direct purchasers" of the drug, and the class action ...
24 Sep, 2008 12:00 pm
At this blog, we root for the drug industry. Film at 11. So the California Court of Appeal's recent decision in Johnson v. GlaxoSmithKline, No.
B199453, slip op. (Cal. Ct. App. Sept. 19, 2008) (link here), left us a little depressed. Several different groups of plaintiffs have sued GlaxoSmithKline pleading that GSK deceptively advertised Paxil as nonhabit-forming. In 2002, plaintiffs filed a motion in federal court to certify a subclass
of "[a]ll persons ...
9 Dec, 2008 9:43 pm
... can be certified later, even if a larger putative class had earlier been denied certification. In Johnson v. GlaxoSmithKline, Inc. (2008)
166 Cal.App.4th 1497, Alvarez has been further distinguished and its reach limited. Where ... California denied class certification in putative class actions brought by current and
former users of the prescription drug Paxil against GlaxoSmithKline, Inc. (GSK), the drug's manufacturer, which alleged GSK had deceptively
advertised Paxil as nonhabit-forming. Relying ...
31 Jan 7:00 am
This one escaped our radar initially. Last month, the California Supreme Court denied a petition for review in Johnson v. Glaxosmithkline
(2008) 166 Cal.App.4th 1497, which we discussed last month in a post found at this link. The case involved the applicability of collateral estoppel to prior orders denying class
certification in actions brought on behalf of a similar putative class.
14 Oct 11:07 am
A Philadelphia court found Tuesday that GlaxoSmithKline failed to warn both doctors and pregnant women of the side affects associated with
Paxil. A 2.5 million dollar settlement was handed down to the family of a ... company guilty of negligence, but not of outrageous conduct. This verdict is the first of about 600
lawsuits that have been filed around the country. GlaxoSmithKline does not agree with the decision and plans to appeal. The following is
information on Paxil from Drugs.com: Paxil is an ...
23 Oct, 2006 2:18 pm
Let's go back to the Court of First Instance's judgment in Case T-168/01 GlaxoSmithKline. We noted it here already. There are a number of
worthwhile general points made in that judgment. One such point is a brief propaedeutic on pleas alleging a breach of Article 81(1) EC and the type of review undertaken by the Court.
The Court of First Instance recalls that several conditions must be satisfied before the prohibition of agreements restrictive of competition laid down in Article 81(1) EC can be ...
12 Feb, 2007 9:37 pm
Watson Pharmaceuticals announced today that it has settled a patent infringement suit concerning GlaxoSmithKline's popular antidepressant
Wellbutrin XL (bupropion HCl extended release tablets) for $35 million. The suit was filed in the Southern District of Florida in December 2005 by Andrx Pharmaceuticals, which was
acquired by Watson last year. Andrx asserted that Glaxo's formulation for Wellbutrin XL infringed its U.S. Patent No. 6,905,708, entitled "Controlled Release Oral Dosage Form." Andrx
...
4 Jun, 2007 1:47 pm
Next week, a congressional subcommittee will investigate the FDA's watchdog role in evaluating the risks associated with the diabetes drug Avandia. One witness, scheduled to appear at
the hearing, claims that Avandia's maker, GlaxoSmithKline, attempted to silence his criticism of the drug. John B. Buse, a nationally
recognized diabetes specialist, says that Glaxo engaged in tactics to intimidate the doctor to keep him from going public with his concerns. The New York Times reports that the ...
Search on: Blawgs.FM | BlawgSearch Google Co-op | Blawg.com | Bloglines | Feedster | Google Blog Search | Technorati | Google | MSN | Yahoo!